Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition Inc., a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, is positioned for significant sales growth driven by its ZUNVEYL oral tablet formulation. The company anticipates meaningful sales advancements as it implements contracting strategies and expands outreach efforts, particularly aiming at neurologists beyond long-term care facilities starting next year. With a projected year-end cash balance of approximately $63 million in 2025, it is expected that Alpha Cognition will have sufficient resources to support operations until it reaches profitability.

Bears say

Alpha Cognition Inc's negative outlook is underscored by a significant revision of the full-year 2025 net sales forecast, which has been decreased from $11.7 million to $5.7 million, reflecting anticipated challenges in contracting and reimbursement processes. Additional risks impacting the company's performance include potential delays in the launch of its lead product ZUNVEYL, slower market uptake due to competitive pressures and pricing issues, and the possibility of setbacks in clinical development. Furthermore, there exists a concern regarding medium- to long-term dilution risk, which could negatively affect investor confidence and the company's financial stability.

ACOG has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACOG has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.